Candida albicans should be considered when managing keratitis in Atopic keratoconjunctivitis.
Division of Ophthalmology and Vision, Department of Clinical Neuroscience, Karolinska Institutet, St. Erik's Eye Hospital, Stockholm, Sweden.
Emma
E
Nivenius
Division of Ophthalmology and Vision, Department of Clinical Neuroscience, Karolinska Institutet, St. Erik's Eye Hospital, Stockholm, Sweden.
Per
P
Montan
D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D002176:Candida albicans / Q000302:isolation & purification*; D002177:Candidiasis / Q000175:diagnosis* / Q000382:microbiology / Q000628:therapy; D003131:Combined Modality Therapy; D003233:Conjunctivitis, Allergic / Q000175:diagnosis* / Q000382:microbiology / Q000628:therapy; D003320:Corneal Ulcer / Q000175:diagnosis* / Q000382:microbiology / Q000628:therapy; D004359:Drug Therapy, Combination; D015818:Eye Infections, Bacterial / Q000175:diagnosis* / Q000382:microbiology / Q000628:therapy; D015821:Eye Infections, Fungal / Q000175:diagnosis* / Q000382:microbiology / Q000628:therapy; D005260:Female; D006801:Humans; D015948:Keratoplasty, Penetrating; D008297:Male; D010866:Natamycin / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000175:diagnosis / Q000382:microbiology / Q000628:therapy; D013211:Staphylococcus aureus / Q000302:isolation & purification
D000935:Antifungal Agents; D000666:Amphotericin B; D010866:Natamycin